Biosimilars: the paradox of sharing the same pharmacological action without full chemical identity

Author： Pani Luca Montilla Simona Pimpinella Giuseppe Bertini Malgarini Renato

ISSN： 1471-2598

Source： Expert Opinion on Biological Therapy, Vol.13, Iss.10, 2013-10, pp. : 1343-1346

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Rituximab biosimilars

By Vital Edward M

Expert Opinion on Biological Therapy, Vol. 13, Iss. 7, 2013-09 ,pp. : 1049-1062

Informa Healthcare

Access to resources Recommend Favorite

Cytotoxic Natural Products and their Pharmacological Mode of Action: A Hypothesis on their Complexity and Spectrum of Activity

Current Enzyme Inhibition, Vol. 8, Iss. 1, 2012-01 ,pp. : 100-103

Bentham Science Publishers

Access to resources Recommend Favorite

Are biosimilars really generics?

By Misra Anoop

Expert Opinion on Biological Therapy, Vol. 10, Iss. 4, 2010-04 ,pp. : 489-494

Informa Healthcare

Access to resources Recommend Favorite

Pharmacovigilance and biosimilars: considerations, needs and challenges

By Casadevall Nicole

Expert Opinion on Biological Therapy, Vol. 13, Iss. 7, 2013-09 ,pp. : 1039-1047

Informa Healthcare

Access to resources Recommend Favorite

Biosimilars: current status and future directions

By Roger Simon D

Expert Opinion on Biological Therapy, Vol. 10, Iss. 7, 2010-07 ,pp. : 1011-1018

Informa Healthcare

Access to resources Recommend Favorite